You are here Home Vaccines Vaccines NeisVac-C Details for NeisVac-C (MenC) vaccine and its components. Listen Print Share Twitter Facebook Email Recently added This page was added on 04 June 2018. Updates made This page was updated on [date-counter-updated-date]. View history of updates Sponsor Pfizer Australia Administration route Intramuscular injection Vaccine group Monovalent vaccines Description: Registered for use in children aged ≥8 weeks and in adults. MenC — monovalent meningococcal serogroup C–tetanus toxoid conjugate vaccine Each 0.5 mL monodose pre-filled syringe contains: 10 µg Neisseria meningitidis serogroup C 10–20 µg tetanus toxoid protein Adsorbed onto 1.4 mg aluminium hydroxide. For Product Information and Consumer Medicine Information about NeisVac-C visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s. Related diseases Meningococcal disease Page history Last updated 4 June 2018 Last reviewed 4 June 2018 Is there anything wrong with this page? Help us improve the Australian Immunisation Handbook What you were doing? (required) What went wrong? (required) Leave this field blank
